Pfizer and BioNTech on Monday said trial results showed their Covid-19 vaccine was safe and produced a robust immune response in children aged five to 11, adding that they would seek regulatory approval shortly.
The vaccine would be administered at a lower dosage than for people over 12, they said. "In participants five to 11 years of age, the vaccine was safe, well tolerated and showed robust neutralising antibody responses," US giant Pfizer and its German partner said in a joint statement.
They plan to submit their data to regulatory bodies in the EU, the US and around the world "as soon as possible". The trial results are the first of their kind for children under 12, with a Moderna trial for six-11 year olds still ongoing.